Title:
NOVEL INDAZOLE COMPOUND OR SALT THEREOF
Document Type and Number:
WIPO Patent Application WO/2020/085493
Kind Code:
A1
Abstract:
An indazole compound represented by general formula (I) or a salt thereof [in the formula, X, R1, R2, ring A, L1, L2, L3, and R5 are as described in the specification].
Inventors:
SAKAMOTO TOSHIHIRO (JP)
KAZUNO HIDEKI (JP)
SUGIMOTO TETSUYA (JP)
KONDO HITOMI (JP)
YAMAMOTO TOMOHIRO (JP)
KAZUNO HIDEKI (JP)
SUGIMOTO TETSUYA (JP)
KONDO HITOMI (JP)
YAMAMOTO TOMOHIRO (JP)
Application Number:
PCT/JP2019/041942
Publication Date:
April 30, 2020
Filing Date:
October 25, 2019
Export Citation:
Assignee:
TAIHO PHARMACEUTICAL CO LTD (JP)
International Classes:
A61K31/416; A61K31/4178; A61K31/422; A61K31/427; A61K31/454; A61K31/496; A61P35/00; A61P43/00; C07D401/14; C07D403/12; C07D403/14; C07D405/14; C07D413/14; C07D417/14
Domestic Patent References:
| WO2018143315A1 | 2018-08-09 | |||
| WO2014152588A1 | 2014-09-25 | |||
| WO2015054572A1 | 2015-04-16 |
Foreign References:
| JP2017528498A | 2017-09-28 | |||
| JP2016532656A | 2016-10-20 | |||
| JP2016519072A | 2016-06-30 | |||
| JP2018202226A | 2018-12-27 | |||
| JP2019075118A | 2019-05-16 |
Other References:
JANES, M. R. ET AL.: "Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor", CELL, vol. 172, no. 3, 25 January 2018 (2018-01-25), pages 578 - 589, XP085348324, Retrieved from the Internet DOI: 10.1016/j.cell.2018.01.006
PATRICELLI, M. P. ET AL.: "Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State", CANCER DISCOVERY, vol. 6, no. 3, 2016, pages 316 - 329, XP055529432, Retrieved from the Internet DOI: 10.1158/2159-8290.CD-15-1105
CHUANG, H. ET AL.: "Pharmacological strategies to target oncogenic KRAS signaling in pancreatic cancer", PHARMACOLOGICAL RESEARCH, vol. 117, 2017, pages 370 - 376, XP029921271, DOI: 10.1016/j.phrs.2017.01.006
NATURE REVIEWS DRUG DISCOVERY, vol. 13, no. 11, 2014, pages 828 - 51
CANCER DISCOV, vol. 6, no. 3, 2016, pages 316 - 29
CELL, vol. 172, no. 3, 2018, pages 578 - 89
GREENEWUTS: "Protective Groups in Organic Synthesis", 2014, JOHN WILEY & SONS INC.
IYAKUHIN NO KAIHATSU: "Molecular Design", vol. 7, 1990, HIROKAWA SHOTEN CO., article "Development of Pharmaceuticals", pages: 163 - 198
See also references of EP 3871673A4
PATRICELLI, M. P. ET AL.: "Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State", CANCER DISCOVERY, vol. 6, no. 3, 2016, pages 316 - 329, XP055529432, Retrieved from the Internet
CHUANG, H. ET AL.: "Pharmacological strategies to target oncogenic KRAS signaling in pancreatic cancer", PHARMACOLOGICAL RESEARCH, vol. 117, 2017, pages 370 - 376, XP029921271, DOI: 10.1016/j.phrs.2017.01.006
NATURE REVIEWS DRUG DISCOVERY, vol. 13, no. 11, 2014, pages 828 - 51
CANCER DISCOV, vol. 6, no. 3, 2016, pages 316 - 29
CELL, vol. 172, no. 3, 2018, pages 578 - 89
GREENEWUTS: "Protective Groups in Organic Synthesis", 2014, JOHN WILEY & SONS INC.
IYAKUHIN NO KAIHATSU: "Molecular Design", vol. 7, 1990, HIROKAWA SHOTEN CO., article "Development of Pharmaceuticals", pages: 163 - 198
See also references of EP 3871673A4
Attorney, Agent or Firm:
SAEGUSA & PARTNERS (JP)
Download PDF: